Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor with Fludarabine and Cytarabine in Pediatric Refractory/Relapsed Leukemia
NCT02212561Phase 1Completed
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Aug 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selinexor in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), mixed phenotype acute leukemia (MPAL) and 1 more, sponsored by St. Jude Children's Research Hospital. Primary endpoints: Maximum Tolerated Dose at Day 35 and Dose Limiting Toxicity at Day 35. Started Aug 2014; status: completed.
02
Drugs
selinexor
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02212561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02212561.